Levide

Levosulpiride, the active ingredient in Levide, is a benzamide antipsychotic presented as an oral dosage form for oral use. It is employed in the management of schizophrenia, other psychotic disorders, functional dyspepsia and gastroparesis, acting on dopamine pathways in adults.

GNH USA supplies Levide as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory support for import and distribution across multiple regions. Customers benefit from reliable supply chains and responsive technical assistance.

Levosulpiride is used to treat disorders involving dopamine dysregulation and gastrointestinal motility. - Schizophrenia: reduces positive and negative symptoms in adult patients. - Psychotic disorders: alleviates acute psychotic episodes and supports maintenance therapy. - Functional dyspepsia: improves upper gastrointestinal discomfort and early satiety. - Gastroparesis: enhances gastric emptying and reduces nausea in patients with delayed gastric motility.

Levosulpiride may cause a range of adverse reactions.

Common Side Effects: - Nausea - Headache - Dizziness - Dry mouth

Serious or Rare Side Effects: - Extrapyramidal symptoms (e.g., dystonia, akathisia) - Hyperprolactinemia - Neuroleptic malignant syndrome

When prescribing Levide, clinicians should consider several safety measures. - Monitor for extrapyramidal symptoms: observe patients for movement disorders. - Assess prolactin levels in long‑term therapy: watch for hormonal disturbances. - Use caution in cardiac disease: evaluate QT interval and arrhythmia risk. - Avoid in patients with known hypersensitivity to levosulpiride or related compounds. - Adjust dose in hepatic impairment: consider reduced clearance. - Store at room temperature below 25°C: keep in the original pack, protect from moisture.

Levide can interact with other medicines; some combinations should be avoided while others require monitoring.

Major Interactions (Avoid): - Monoamine oxidase (MAO) inhibitors: risk of severe hypertensive reactions. - Other potent D2 antagonists: additive antipsychotic effects may increase side‑effect burden. - QT‑prolonging drugs: heightened potential for cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CYP2D6 inhibitors: may increase levosulpiride plasma concentrations. - Anticholinergic agents: can exacerbate dry mouth and constipation. - Central nervous system depressants: may enhance sedation and dizziness.